Crown Bioscience is a global CRO providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases
New Crown Bioscience Publication Details Application of In Vitro 3D Organoids with Matched PDX for Clinically Relevan...
The paper is the first comprehensive review of tumor organoids derived from Patient Derived Xenograft (PDX) models across multiple cancer types.
Crown Bioscience & MBL, a joint venture between two JSR Life Sciences companies formed earlier this year, announce today the launch of their full-service drug discovery and development capabilities...
Crown Bioscience Appoints Michael Prosser as Chief Business Officer and Illustrates Further Investment in Commercial ...
Crown Bioscience announced today that it has restructured its commercial leadership team by creating a new Chief Business Officer (CBO) role and with additional investment in commercial talent.
Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanese Customers
Crown Bioscience and MBL announce the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers.
First Clinical Candidate Developed using HUB Organoids® and High Content Screening Targets Cancer Stem Cells in Solid...
Crown Bioscience, a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of preclinical data in the journal, Nature Cancer, on a bispecific antibody which prevents the...
Upgraded facility increases capacity for in vivo services by 30 percent and adds high frequency ultrasound capabilities to the company’s preclinical capabilities